What are you looking for?

Library
Poster
Full Title

iTRAQ approach to investigate the impact of cigarette smoke, smoking cessation and switching to a prototypic modified risk tobacco product on the lung proteome of C57BL/6 mice


Authored by  E Veljkovic, J Hoeng, M Peitsch, NV Ivanov, F Martin

Abstract

Reliable system-wide measurements are key to a meaningful systems-toxicology approach by which impact of toxicants in cells are evaluated (Hoeng et al., 2012). While still being challenging to setup, liquid-chromatography mass-spectrometry (LC-MS) based quantitative proteomics may lead to a further understanding of systems response and complement the widely used transcriptomics data. In the context of a life-long animal study aiming at characterizing the impact of cigarette smoke in mouse lung and the effect of cessation and switching to a prototypic Modified Risk Tobacco Product (pMRTP), we established an isobaric tags for absolute and relative quantification (iTRAQ®)-based pipeline aiming at capturing a wide variety of proteins. The arms of  this animal study involving C57/Bl6 mice were exposure to: (i) fresh-air only, (ii) conventional cigarette smoke (CS) from 3R4F cigarettes (from University of Kentucky),  (iii) CS and switch to a pMRTP,  (iv) CS and switch to fresh air (cessation) and (v) pMRTP only. 

itraq-approach-to-investigate-the-impact-of-cigarette-smoke-smoking-cessation-and-switching-to-a-pro

PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

Our RRPs

Reduced-risk products ("RRPs") is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continued smoking. We have a range of RRPs in various stages of development, scientific assessment and commercialization. Because our RRPs do not burn tobacco, they produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.